Pharmaceutical / Drug Definition :
Increases production of cyclic adenosine monophosphate at beta-adrenergic receptors, producing bronchodilation and inhibiting histamine release. Primarily selective for beta2-adrenergic (pulmonary) receptors, with minimal effect on beta1-adrenergic (cardiac) receptors.
In the United States, Pirbuterol Acetate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Pirbuterol Acetate.
FDA Label Requirements and Exceptions
FDA Import Information
Pirbuterol Acetate (Pirbuterol Acetate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Pirbuterol Acetate (Pirbuterol Acetate Suppliers)
- Processors Pirbuterol Acetate
- Repackers Pirbuterol Acetate
- Relabelers Pirbuterol Acetate
- Exporters Pirbuterol Acetate
- Importers Pirbuterol Acetate
For more information about Pirbuterol Acetate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.